Literature DB >> 22634584

Suicide gene therapy in cancer: where do we stand now?

Sónia Duarte1, Georges Carle, Henrique Faneca, Maria C Pedroso de Lima, Valérie Pierrefite-Carle.   

Abstract

Suicide gene therapy is based on the introduction into tumor cells of a viral or a bacterial gene, which allows the conversion of a non-toxic compound into a lethal drug. Although suicide gene therapy has been successfully used in a large number of in vitro and in vivo studies, its application to cancer patients has not reached the desirable clinical significance. However, recent reports on pre-clinical cancer models demonstrate the huge potential of this strategy when used in combination with new therapeutic approaches. In this review, we summarize the different suicide gene systems and gene delivery vectors addressed to cancer, with particular emphasis on recently developed systems and associated bystander effects. In addition, we review the different strategies that have been used in combination with suicide gene therapy and provide some insights into the future directions of this approach, particularly towards cancer stem cell eradication.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22634584     DOI: 10.1016/j.canlet.2012.05.023

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  65 in total

1.  Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells.

Authors:  R Sayroo; D Nolasco; Z Yin; Y Colon-Cortes; M Pandya; C Ling; G Aslanidi
Journal:  Gene Ther       Date:  2015-10-08       Impact factor: 5.250

2.  A Lentiviral Vector Expressing Desired Gene Only in Transduced Cells: An Approach for Suicide Gene Therapy.

Authors:  Zahra Mohammadi; Laleh Shariati; Hossein Khanahmad; Mahsa Kolahdouz; Fariborz Kianpoor; Jahan Afrooz Ghanbari; Zahra Hejazi; Mansoor Salehi; Parvaneh Nikpour; Mohammad Amin Tabatabaiefar
Journal:  Mol Biotechnol       Date:  2015-09       Impact factor: 2.695

Review 3.  Progress and problems with the use of suicide genes for targeted cancer therapy.

Authors:  Zahra Karjoo; Xuguang Chen; Arash Hatefi
Journal:  Adv Drug Deliv Rev       Date:  2015-05-22       Impact factor: 15.470

Review 4.  Gene-directed enzyme prodrug therapy.

Authors:  Jin Zhang; Vijay Kale; Mingnan Chen
Journal:  AAPS J       Date:  2014-10-23       Impact factor: 4.009

Review 5.  Adenovirus: the first effective in vivo gene delivery vector.

Authors:  Ronald G Crystal
Journal:  Hum Gene Ther       Date:  2014-01       Impact factor: 5.695

Review 6.  Recent advances and future of immunotherapy for glioblastoma.

Authors:  Neha Kamran; Alexandra Calinescu; Marianela Candolfi; Mayuri Chandran; Yohei Mineharu; Antonela S Asad; Carl Koschmann; Felipe J Nunez; Pedro R Lowenstein; Maria G Castro
Journal:  Expert Opin Biol Ther       Date:  2016-07-27       Impact factor: 4.388

Review 7.  Protein engineering: a new frontier for biological therapeutics.

Authors:  Peter H Tobin; David H Richards; Randolph A Callender; Corey J Wilson
Journal:  Curr Drug Metab       Date:  2014       Impact factor: 3.731

8.  Current status of gene therapy for brain tumors.

Authors:  Andrea M Murphy; Samuel D Rabkin
Journal:  Transl Res       Date:  2012-12-11       Impact factor: 7.012

9.  Suicide Gene Therapy for Cancer - Current Strategies.

Authors:  Paul Zarogoulidis; Kaid Darwiche; Antonios Sakkas; Lonny Yarmus; Haidong Huang; Qiang Li; Lutz Freitag; Konstantinos Zarogoulidis; Marek Malecki
Journal:  J Genet Syndr Gene Ther       Date:  2013-08-09

10.  Inhibition of homologous recombination with vorinostat synergistically enhances ganciclovir cytotoxicity.

Authors:  Brendon Ladd; Jeffrey J Ackroyd; J Kevin Hicks; Christine E Canman; Sheryl A Flanagan; Donna S Shewach
Journal:  DNA Repair (Amst)       Date:  2013-11-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.